Detalhe da pesquisa
1.
How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy.
Blood
; 141(20): 2452-2459, 2023 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36827628
2.
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.
Blood
; 139(3): 413-423, 2022 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34570876
3.
Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Int J Mol Sci
; 24(9)2023 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37176053
4.
T-cell lymphoma: the CAR-T revolution is coming.
Blood
; 143(13): 1201-1202, 2024 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38546636
5.
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival.
Eur J Haematol
; 107(3): 301-310, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33973276
6.
Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era.
Am J Hematol
; 96(11): 1374-1384, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34324220
7.
Challenges of driving CD30-directed CAR-T cells to the clinic.
BMC Cancer
; 19(1): 203, 2019 Mar 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30841880
8.
Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Cancer
; 124(11): 2306-2315, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29579328
9.
Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity.
Blood
; 137(23): 3306-3309, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33624095
10.
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
Br J Haematol
; 175(2): 281-289, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27448091
11.
Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis.
Leukemia
; 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38750138
12.
Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+ lymphoma: a phase 1 study.
Lancet Haematol
; 11(5): e358-e367, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38555923
13.
Building safety into CAR-T therapy.
Hum Vaccin Immunother
; 19(3): 2275457, 2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37968136
14.
Cellular Therapies in Chronic Lymphocytic Leukemia and Richter's Transformation: Recent Developments in Chimeric Antigen Receptor T-Cells, Natural Killer Cells, and Allogeneic Stem Cell Transplant.
Cancers (Basel)
; 15(6)2023 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36980726
15.
The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure.
Hematology Am Soc Hematol Educ Program
; 2023(1): 510-518, 2023 Dec 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38066906
16.
Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.
J Clin Oncol
; 41(3): 541-554, 2023 01 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35763708
17.
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas.
J Immunother Cancer
; 11(8)2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37527906
18.
Wearable sensor-based performance status assessment in cancer: A pilot multicenter study from the Alliance for Clinical Trials in Oncology (A19_Pilot2).
PLOS Digit Health
; 2(1): e0000178, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36812616
19.
A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
Leuk Lymphoma
; 64(1): 107-118, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36323309
20.
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study.
J Hematol Oncol
; 16(1): 49, 2023 05 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37158890